<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="85765"><DrugName>calculus bovis sativus, Wuhan Jianmin Dapeng Pharmaceutical</DrugName><DrugSynonyms><Name><Value>calculus bovis sativus, Wuhan Jianmin Dapeng Pharmaceutical</Value></Name></DrugSynonyms><CompanyOriginator id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1085195" type="Company"><TargetEntity id="5035756756" type="organizationId">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"></TargetEntity><TargetEntity id="345" type="ICD9"></TargetEntity><TargetEntity id="10015037" type="MEDDRA"></TargetEntity><TargetEntity id="D004827" type="MeSH"></TargetEntity><TargetEntity id="-2005570698" type="omicsDisease"></TargetEntity><TargetEntity id="115" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3081" type="ciIndication"><TargetEntity id="10000269" type="MEDDRA"></TargetEntity><TargetEntity id="D000038" type="MeSH"></TargetEntity><TargetEntity id="-473240105" type="omicsDisease"></TargetEntity><TargetEntity id="870" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="665" type="ciIndication"><TargetEntity id="10028034" type="MEDDRA"></TargetEntity><TargetEntity id="D019226" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="717" type="ciIndication"><TargetEntity id="10039911" type="MEDDRA"></TargetEntity><TargetEntity id="D012640" type="MeSH"></TargetEntity><TargetEntity id="-1663650866" type="omicsDisease"></TargetEntity><TargetEntity id="4242" type="siCondition"></TargetEntity><TargetEntity id="1353" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Abscess - China - Dec-2003</FirstLaunched><FirstLaunched>Epilepsy - China - Dec-2003</FirstLaunched><FirstLaunched>Mouth ulcer - China - Dec-2003</FirstLaunched><FirstLaunched>Seizure disorder - China - Dec-2003</FirstLaunched><FirstLaunched>Stroke - China - Dec-2003</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="119">Epilepsy</Indication><Indication id="3081">Abscess</Indication><Indication id="65">Stroke</Indication><Indication id="665">Mouth ulcer</Indication><Indication id="717">Seizure disorder</Indication></IndicationsPrimary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="70">Anticonvulsant agent</Action></ActionsSecondary><Technologies><Technology id="614">Powder formulation dermatological</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="896">Formulation solid oral</Technology></Technologies><EphmraCodes><Ephmra><Code>N3</Code><Name>ANTI-EPILEPTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2014-01-20T08:35:48.000Z</LastModificationDate><ChangeDateLast>2013-06-20T00:00:00.000Z</ChangeDateLast><AddedDate>2013-06-20T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1085195"&gt;Wuhan Jianmin Dapeng Pharmaceutical&lt;/ulink&gt; has developed and launched calculus bovis sativus for the oral or dermatological treatment of stroke, seizure, epilepsy, sore throat, mouth ulcers, swollen welling-abscess and boils. The product was assumed to be launched in China shortly after its approval there in 2003 [&lt;ulink linkType="Reference" linkID="1440151"&gt;1440151&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1440156"&gt;1440156&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In 1997, the product was categorizard as a class 1 traditional Chinese medicine by the SFDA [&lt;ulink linkType="Reference" linkID="1440151"&gt;1440151&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440151" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440151" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="717">Seizure disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440151" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3081">Abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440151" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="665">Mouth ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440151" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="717">Seizure disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="665">Mouth ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085195">Wuhan Jianmin Dapeng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3081">Abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="1440156" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1028161" number="CN-01164276" title="Method of in vitro culturing medicine ox gallstone with natural ox gall"></PatentFamily><PatentFamily id="1491629" number="CN-102512451" title="Method for preparing cattle gall-stone from fermented fel bovis and composite calcium bilirubinate"></PatentFamily><PatentFamily id="2083816" number="CN-102512457" title="Method for preparing composite calcium bilirubinate from ox gall"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jianmin Pharmaceutical Group Co Ltd" id="1085194"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>